Global Generic Anti-cancer Injectables Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR052500775

Publication Date:

May 1, 2025

Pages:

114

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Generic Anti-cancer Injectables market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

This report is a detailed and comprehensive analysis for global Generic Anti-cancer Injectables market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Generic Anti-cancer Injectables market size and forecasts, in consumption value ($ Million), 2020-2031
Global Generic Anti-cancer Injectables market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Generic Anti-cancer Injectables market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Generic Anti-cancer Injectables market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Generic Anti-cancer Injectables
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Generic Anti-cancer Injectables market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Teva, Viatris, Biocon, Amgen, Sandoz (Novartis), Pfizer, Qilu Pharmaceutical, Jiangsu Hansoh, CTTQ, Jiangsu Hengrui, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Generic Anti-cancer Injectables market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Bevacizuma
Rituximab
Herceptin
Paclitaxel
Others
Market segment by Application
Hospital
Retail
Market segment by players, this report covers
Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Generic Anti-cancer Injectables product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Generic Anti-cancer Injectables, with revenue, gross margin, and global market share of Generic Anti-cancer Injectables from 2020 to 2025.
Chapter 3, the Generic Anti-cancer Injectables competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Generic Anti-cancer Injectables market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Generic Anti-cancer Injectables.
Chapter 13, to describe Generic Anti-cancer Injectables research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Generic Anti-cancer Injectables by Type
1.3.1 Overview: Global Generic Anti-cancer Injectables Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Generic Anti-cancer Injectables Consumption Value Market Share by Type in 2024
1.3.3 Bevacizuma
1.3.4 Rituximab
1.3.5 Herceptin
1.3.6 Paclitaxel
1.3.7 Others
1.4 Global Generic Anti-cancer Injectables Market by Application
1.4.1 Overview: Global Generic Anti-cancer Injectables Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Retail
1.5 Global Generic Anti-cancer Injectables Market Size & Forecast
1.6 Global Generic Anti-cancer Injectables Market Size and Forecast by Region
1.6.1 Global Generic Anti-cancer Injectables Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Generic Anti-cancer Injectables Market Size by Region, (2020-2031)
1.6.3 North America Generic Anti-cancer Injectables Market Size and Prospect (2020-2031)
1.6.4 Europe Generic Anti-cancer Injectables Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Generic Anti-cancer Injectables Market Size and Prospect (2020-2031)
1.6.6 South America Generic Anti-cancer Injectables Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Generic Anti-cancer Injectables Market Size and Prospect (2020-2031)
2 Company Profiles
2.1 Teva
2.1.1 Teva Details
2.1.2 Teva Major Business
2.1.3 Teva Generic Anti-cancer Injectables Product and Solutions
2.1.4 Teva Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Teva Recent Developments and Future Plans
2.2 Viatris
2.2.1 Viatris Details
2.2.2 Viatris Major Business
2.2.3 Viatris Generic Anti-cancer Injectables Product and Solutions
2.2.4 Viatris Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Viatris Recent Developments and Future Plans
2.3 Biocon
2.3.1 Biocon Details
2.3.2 Biocon Major Business
2.3.3 Biocon Generic Anti-cancer Injectables Product and Solutions
2.3.4 Biocon Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Biocon Recent Developments and Future Plans
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Generic Anti-cancer Injectables Product and Solutions
2.4.4 Amgen Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Amgen Recent Developments and Future Plans
2.5 Sandoz (Novartis)
2.5.1 Sandoz (Novartis) Details
2.5.2 Sandoz (Novartis) Major Business
2.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Product and Solutions
2.5.4 Sandoz (Novartis) Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Sandoz (Novartis) Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Generic Anti-cancer Injectables Product and Solutions
2.6.4 Pfizer Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Qilu Pharmaceutical
2.7.1 Qilu Pharmaceutical Details
2.7.2 Qilu Pharmaceutical Major Business
2.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Product and Solutions
2.7.4 Qilu Pharmaceutical Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Qilu Pharmaceutical Recent Developments and Future Plans
2.8 Jiangsu Hansoh
2.8.1 Jiangsu Hansoh Details
2.8.2 Jiangsu Hansoh Major Business
2.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Product and Solutions
2.8.4 Jiangsu Hansoh Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Jiangsu Hansoh Recent Developments and Future Plans
2.9 CTTQ
2.9.1 CTTQ Details
2.9.2 CTTQ Major Business
2.9.3 CTTQ Generic Anti-cancer Injectables Product and Solutions
2.9.4 CTTQ Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 CTTQ Recent Developments and Future Plans
2.10 Jiangsu Hengrui
2.10.1 Jiangsu Hengrui Details
2.10.2 Jiangsu Hengrui Major Business
2.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Product and Solutions
2.10.4 Jiangsu Hengrui Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Jiangsu Hengrui Recent Developments and Future Plans
2.11 CSPC
2.11.1 CSPC Details
2.11.2 CSPC Major Business
2.11.3 CSPC Generic Anti-cancer Injectables Product and Solutions
2.11.4 CSPC Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 CSPC Recent Developments and Future Plans
2.12 Innovent Biologics
2.12.1 Innovent Biologics Details
2.12.2 Innovent Biologics Major Business
2.12.3 Innovent Biologics Generic Anti-cancer Injectables Product and Solutions
2.12.4 Innovent Biologics Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Innovent Biologics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Generic Anti-cancer Injectables Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Generic Anti-cancer Injectables by Company Revenue
3.2.2 Top 3 Generic Anti-cancer Injectables Players Market Share in 2024
3.2.3 Top 6 Generic Anti-cancer Injectables Players Market Share in 2024
3.3 Generic Anti-cancer Injectables Market: Overall Company Footprint Analysis
3.3.1 Generic Anti-cancer Injectables Market: Region Footprint
3.3.2 Generic Anti-cancer Injectables Market: Company Product Type Footprint
3.3.3 Generic Anti-cancer Injectables Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Generic Anti-cancer Injectables Consumption Value and Market Share by Type (2020-2025)
4.2 Global Generic Anti-cancer Injectables Market Forecast by Type (2026-2031)
5 Market Size Segment by Application
5.1 Global Generic Anti-cancer Injectables Consumption Value Market Share by Application (2020-2025)
5.2 Global Generic Anti-cancer Injectables Market Forecast by Application (2026-2031)
6 North America
6.1 North America Generic Anti-cancer Injectables Consumption Value by Type (2020-2031)
6.2 North America Generic Anti-cancer Injectables Market Size by Application (2020-2031)
6.3 North America Generic Anti-cancer Injectables Market Size by Country
6.3.1 North America Generic Anti-cancer Injectables Consumption Value by Country (2020-2031)
6.3.2 United States Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
6.3.3 Canada Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
6.3.4 Mexico Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
7 Europe
7.1 Europe Generic Anti-cancer Injectables Consumption Value by Type (2020-2031)
7.2 Europe Generic Anti-cancer Injectables Consumption Value by Application (2020-2031)
7.3 Europe Generic Anti-cancer Injectables Market Size by Country
7.3.1 Europe Generic Anti-cancer Injectables Consumption Value by Country (2020-2031)
7.3.2 Germany Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
7.3.3 France Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
7.3.5 Russia Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
7.3.6 Italy Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Generic Anti-cancer Injectables Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Generic Anti-cancer Injectables Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region
8.3.1 Asia-Pacific Generic Anti-cancer Injectables Consumption Value by Region (2020-2031)
8.3.2 China Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
8.3.3 Japan Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
8.3.4 South Korea Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
8.3.5 India Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
8.3.7 Australia Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
9 South America
9.1 South America Generic Anti-cancer Injectables Consumption Value by Type (2020-2031)
9.2 South America Generic Anti-cancer Injectables Consumption Value by Application (2020-2031)
9.3 South America Generic Anti-cancer Injectables Market Size by Country
9.3.1 South America Generic Anti-cancer Injectables Consumption Value by Country (2020-2031)
9.3.2 Brazil Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
9.3.3 Argentina Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Generic Anti-cancer Injectables Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Generic Anti-cancer Injectables Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country
10.3.1 Middle East & Africa Generic Anti-cancer Injectables Consumption Value by Country (2020-2031)
10.3.2 Turkey Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
10.3.4 UAE Generic Anti-cancer Injectables Market Size and Forecast (2020-2031)
11 Market Dynamics
11.1 Generic Anti-cancer Injectables Market Drivers
11.2 Generic Anti-cancer Injectables Market Restraints
11.3 Generic Anti-cancer Injectables Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Generic Anti-cancer Injectables Industry Chain
12.2 Generic Anti-cancer Injectables Upstream Analysis
12.3 Generic Anti-cancer Injectables Midstream Analysis
12.4 Generic Anti-cancer Injectables Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂